Frontlight ResearchEarly access
TerminatedPhase 2
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
Key facts
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Where
- Chapel Hill, Falls Church, Gainesville, Hannibal, Houston, Iowa City, Kansas City, New York, Orlando, and Salt Lake City, United StatesSee the 10 sitesAlso in 3 other countries, 3 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 14 people enrolled
- Started
- 23 Feb 2023
- Ended
- 19 Aug 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- VX-864
- Record updated
- 8 September 2025
- Why it stopped
- Study drug dosing was permanently discontinued at the Sponsor's discretion based on frequency and nature of skin and subcutaneous tissue disorders.
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participants must have a PiZZ genotype confirmed at screening
- Plasma AAT levels indicating severe deficiency at screening
Who cannot take part
- Solid organ, or hematological transplantation or is currently on a transplant list
- History of use of gene therapy or Ribonucleic acid interference (RNAi) therapy at any time previously
- Participants for whom discontinuation of augmentation therapy is not considered to be in their best interest, based on the clinical judgement of the treating physician; Other protocol defined Inclusion/Exclusion criteria may apply
- History of a medical condition that could negatively impact the ability to complete the study
Where in United States
Also in 3 other countries, 3 sites
- Marsico Clinical Research Center at UNC Pulmonary ClinicChapel Hill, United States
- Inova Fairfax Medical CampusFalls Church, United States
- University of FloridaGainesville, United States
- Hannibal Regional Healthcare SystemHannibal, United States
- Renovatio ClinicalHouston, United States
- The University of Iowa Hospitals and Clinics: Adult Pulmonary ClinicIowa City, United States
- University of Kansas Medical CenterKansas City, United States
- Columbia University Irving Medical CenterNew York, United States
- Central Florida Pulmonary Group, P.A.Orlando, United States
- University Of Utah HealthSalt Lake City, United States
About the trial
What the trial wants to find out
The purpose of this study evaluates the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.
The 2 groups in the trial
- Group ATreatment being tested
Participants received VX-864 every 12 hours (q12h) for 48 weeks or until study drug dosing was terminated.
Treatment: VX-864
- Group BTreatment being tested
Participants undergo a liver biopsy before receiving VX-864 q12h for 48 weeks or until study drug dosing was terminated, and undergo a second liver biopsy at either Week 24 or Week 48.
Treatment: VX-864
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
- Record updated
- 8 September 2025